To accelerate the discovery of aptamers and be the leading provider of aptamer based sensing technologies.
AptaMatrix is a privately held, start-up biotechnology company headquartered in Syracuse, New York. The company’s focus is to accelerate the rate of aptamer discovery using its patent pending High Throughput Screening of Aptamers (HTSA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of a) creating rapid diagnostic tools for detection of chemical and biological targets, and b) leveraging this diagnostic platform for drug discovery applications. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. HTSA and AlloSwitch solutions are built on patented biotechnology based on years of leading-edge biological research and industry partnerships at Syracuse University.
The HTSA approach leverages the high throughput capabilities of deep-sequencing technology. All sequencing activity is managed by our Genomics Division and conducted on our Illumina GAIIx platforms. Data analysis is supported by our in-house bioinformatics team. In addition to supporting internal research and development, our genomics division actively supports both academic and commercial deep-sequencing projects.
Philip N. Borer, Ph.D.
CEO, Chairman of the Board
Phil provides the strategic vision that is taking AptaMatrix from academia to commercialization. His ground-breaking research is at the core of both the HTSA method and the AlloSwitch technology. The AlloSwitch concept was developed at Syracuse University in collaboration with Bruce Hudson as an ultrasensitive method to detect binding to the nucleocapsid protein from HIV-1. He is a principal author of SBIR and STTR grants to support the company’s R&D efforts. Also a Professor of Chemistry at SU, Phil specializes in the structure and stability of nucleic acids and their complexes with proteins. After receiving his Ph.D. from the University of California at Berkeley in 1972, he held a postdoctoral fellowship at Johns Hopkins. He was a member of the Berkeley team that developed the first rules for the stability of base-paired RNA and DNA structures. Phil was also a consultant, staff scientist, then Director of Research and Development for New Methods Research, Inc. (NMRi), which created and sold software for use in chemical and biochemical analysis.
Peter E. Kent
President, Board Member
Peter directs AptaMatrix’s overall business and operational strategy, including high-level product development and key industry partnerships. He has extensive experience in successful startup businesses and generating capital. As President of New Methods Research, he took the company from a staff of 6 to worldwide sales of $5 million and #140 on the INC 500 list within two years. As Manager of New Product Developments for Mechanical Technology Inc., he took a research concept for diagnostic and balancing gas turbine engines to a product that has been sold to airlines in over 50 countries. Peter is a licensed Professional Engineer, who has also managed a public water system, is familiar with methods for monitoring water quality and has many contacts in this key area for AptaMatrix sensor development. He received his BME and MBA from Rensselaer Polytechnic Institute.
Mark P. McPike, Ph.D.
Chief Science Officer
Mark spearheads the company’s research and development efforts. A principal author of SBIR & STTR efforts, he is also the Principal Investigator on a several recently awarded SBIR grant from NIH and Homeland Security Advanced Research Projects Agency (HSARPA). Mark joined AptaMatrix (formerly OrthoSystems) in 2003 with a strong commitment to develop rapid and sensitive detectors for chemical and biological agents under the AlloSwitch project (formerly OrthoSwitch project). This sensor program was directed toward environmental and terrorist threats to public health. Mark is efforts are currently focused on commercializing the HTSA discovery platform which is a critical area for company growth. He received his Ph.D. in Chemistry from Syracuse University in 2001. Prior to joining the company, Mark was an American Foundation for AIDS Research Fellow at the Dana-Farber Cancer Institute at Harvard Medical School, focused on screening small molecules for anti-viral activity.
Bruce S. Hudson, Ph.D.
Bruce focuses on high sensitivity readout technologies to determine the state of AptaMatrix’s AlloSwitch™ sensors. His background in spectroscopy and analyzing ligand binding to macromolecules is a key to our success. Bruce and Phil have collaborated for many years in anti-AIDS research. While that focus continues, it became clear that AlloSwitch technology had wide application in contaminant sensing and drug discovery. Bruce is a principal author of SBIR and STTR grants to support R&D efforts at AptaMatrix. Bruce is also a Professor of Chemistry at Syracuse University where he specializes in biochemical applications of fluorescence spectroscopy and in neutron scattering and diffraction. He is an expert in thermodynamics and chemical kinetics. He received his Ph.D. from Harvard University in 1972, and has held positions at Stanford and the University of Oregon prior to coming to Syracuse University.